<DOC>
	<DOCNO>NCT00335686</DOCNO>
	<brief_summary>The study aim evaluate change mitochondrial DNA ( mDNA ) mean mDNA/nuclearDNA ( nDNA ) ratio marker mitochondrial toxicity follow interruption nucleoside analogue .</brief_summary>
	<brief_title>Study Effect Kaletra + Nevirapine Maintenance Bitherapy Compared Triple Therapy Including Kaletra + Analogues HIV Patients</brief_title>
	<detailed_description>At moment know mitochondrial toxicity main pathogenic mechanism toxicity associate nucleoside analogue , include lipoatrophy , facial level stigmatise factor patient HIV infection . The primary outcome measure design `` NTRI-sparing '' bitherapy retard onset mitochondrial toxicity reverse , mainly regard loss subcutaneous fat lipoatrophy . Lopinavir/ritonavir nevirapine two antiretrovirals different mutation pattern high antiviral potency . Their combination therefore guarantee antiviral success . The NEKA study endorse efficacy immunologically virologically ( Negredo E. et al , NRTI-sparing regimen . XIV International AIDS Conference . Barcelona 2002 . LB PeB9021 ) . Similarly , protective effect nevirapine lipid metabolism would counteract negative impact attribute lopinavir/ritonavir , reduce cardiovascular risk patient .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>1 . Age &gt; = 18 year . 2 . HIV1 infect patient . 3 . Patients HAART therapy PIs NNRTIs . 4 . Patients undetectable viral load ( &lt; 50/80 copies/mL ) last 6 month ( least 2 determination separate 2 month ) . 5 . Hepatic test &lt; 5 time normal value . 6 . Subject able follow treatment period . 7 . Women may fertile age ( define least one year menopause undergoing surgical sterilisation technique ) , must undertake use barrier contraceptive method study . 8 . Signature inform consent 1 . Presence opportunistic infection and/or recent tumour ( &lt; 6 month ) . 2 . Suspicion resistance document resistance investigational drug . 3 . Suspicion possible bad adherence . 4 . Pregnancy breastfeeding ; refusal follow reliable contraception treatment period . 5 . Known allergic hypersensitivity investigational drug similar drug . 6 . Patients participate another clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Mitochondrial toxicity</keyword>
	<keyword>Lopinavir-rtv</keyword>
	<keyword>Nevirapine</keyword>
	<keyword>DNA mitochondrial/DNA nuclear</keyword>
</DOC>